CA2150477A1 - Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates - Google Patents

Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates

Info

Publication number
CA2150477A1
CA2150477A1 CA002150477A CA2150477A CA2150477A1 CA 2150477 A1 CA2150477 A1 CA 2150477A1 CA 002150477 A CA002150477 A CA 002150477A CA 2150477 A CA2150477 A CA 2150477A CA 2150477 A1 CA2150477 A1 CA 2150477A1
Authority
CA
Canada
Prior art keywords
residue
precursor
reagent
oligonucleotide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002150477A
Other languages
English (en)
Inventor
Robert Allen Snow
Eric S. Groves
Clyde William Shearman
Ashis K. Saha
Arup Sen
Christopher Douglas Valiant Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2150477A1 publication Critical patent/CA2150477A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002150477A 1992-11-30 1993-11-30 Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates Abandoned CA2150477A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98569992A 1992-11-30 1992-11-30
US985699 1997-12-05

Publications (1)

Publication Number Publication Date
CA2150477A1 true CA2150477A1 (fr) 1994-06-09

Family

ID=25531717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002150477A Abandoned CA2150477A1 (fr) 1992-11-30 1993-11-30 Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates

Country Status (5)

Country Link
EP (1) EP0680335A1 (fr)
JP (1) JPH08503854A (fr)
AU (1) AU5733994A (fr)
CA (1) CA2150477A1 (fr)
WO (1) WO1994012216A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639083B1 (fr) * 1992-05-07 2001-07-18 Nycomed Imaging As Complexants et immunoreactifs de ciblage
US8063190B2 (en) * 1998-06-02 2011-11-22 Tom Robin Caine Boyde Nucleic acid-linked conjugates and methods for making and using them
EP1991577A2 (fr) 2006-01-31 2008-11-19 Parkinson, John F. Modulation de l'activite mdl-1 pour le traitement de maladies inflammatoires
JP2008297203A (ja) * 2007-05-29 2008-12-11 Chisso Corp 複合体
EP2005970A1 (fr) 2007-06-22 2008-12-24 Berlin Science Partners GmbH i.V. Imagerie Diagnostique par combinaison de moyens de contraste
EP2072060A1 (fr) 2007-12-18 2009-06-24 Institut Curie Procédés et compositions pour la préparation et l'utilisation de conjugués de toxines
GB2519906B (en) 2012-08-13 2017-02-08 Univ California Methods for detecting target nucleic acids in sample lysate droplets
US10697007B2 (en) 2014-06-27 2020-06-30 The Regents Of The University Of California PCR-activated sorting (PAS)
EP3209419A4 (fr) 2014-10-22 2018-10-03 The Regents of The University of California Imprimante à microgouttelettes haute définition
CN115011670A (zh) * 2015-02-04 2022-09-06 加利福尼亚大学董事会 通过在离散实体中条形码化对核酸进行测序
US11142791B2 (en) 2016-08-10 2021-10-12 The Regents Of The University Of California Combined multiple-displacement amplification and PCR in an emulsion microdroplet
AU2017382905A1 (en) 2016-12-21 2019-07-04 The Regents Of The University Of California Single cell genomic sequencing using hydrogel based droplets
US10501739B2 (en) 2017-10-18 2019-12-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
WO2021003255A1 (fr) 2019-07-01 2021-01-07 Mission Bio Procédé et appareil pour normaliser des lectures quantitatives dans des expériences à cellule unique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587044A (en) * 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides

Also Published As

Publication number Publication date
EP0680335A1 (fr) 1995-11-08
AU5733994A (en) 1994-06-22
JPH08503854A (ja) 1996-04-30
WO1994012216A1 (fr) 1994-06-09

Similar Documents

Publication Publication Date Title
US6248870B1 (en) Unsymmetrical complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
CA2223261C (fr) Apport ameliore d'agents diagnostiques ou therapeutiques a un site cible
US5760191A (en) Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
JP3292301B2 (ja) 治療用及び診断用撮像組成物及び方法において役立つ錯化剤及びターゲティング放射性免疫試薬
CA1260827A (fr) Complexes anticorps - ions metalliques
CA2150477A1 (fr) Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates
US5733523A (en) Targeted delivery of a therapeutic entity using complementary oligonucleotides
CA2157902A1 (fr) Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates
JP3143506B2 (ja) 治療用物質の標的送達用医薬組成物
EP0675737A1 (fr) Reactifs a reactivite immunologique utilisant la dihydrofolate reductase
RU2122431C1 (ru) Радиоактивный иммунореагент направленного действия, композиция для получения изображения злокачественного новообразования в организме, способ получения изображения и комплексообразующий агент
AU7244894A (en) Immunoreactive reagents employing monoamine oxidase
AU6128694A (en) Immunoreactive reagents employing heterodimers
WO1997033626A1 (fr) Nouveaux chelateurs et compositions preparees a l'aide de ceux-ci
US7713528B1 (en) Method for in vivo delivery of active compounds using reagent conjugate

Legal Events

Date Code Title Description
FZDE Dead